Market closed
BridgeBio Pharma/$BBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Ticker
$BBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
728
ISIN
US10806X1028
Website
BridgeBio Pharma Metrics
BasicAdvanced
$6.4B
-
-$3.54
1.08
-
Price and volume
Market cap
$6.4B
Beta
1.08
52-week high
$39.54
52-week low
$21.62
Average daily volume
3.3M
Financial strength
Current ratio
4.57
Quick ratio
4.312
Long term debt to equity
-113.082
Total debt to equity
-113.4
Interest coverage (TTM)
-5.67%
Management effectiveness
Return on assets (TTM)
-48.27%
Return on equity (TTM)
50.59%
Valuation
Price to revenue (TTM)
49.912
Price to book
-3.88
Price to tangible book (TTM)
-3.81
Price to free cash flow (TTM)
-12.484
Growth
Revenue change (TTM)
-41.71%
Earnings per share change (TTM)
11.20%
3-year revenue growth (CAGR)
21.55%
3-year earnings per share growth (CAGR)
-4.64%
What the Analysts think about BridgeBio Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.
BridgeBio Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BridgeBio Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BridgeBio Pharma News
AllArticlesVideos
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·16 hours ago
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
GlobeNewsWire·2 days ago
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
GlobeNewsWire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BridgeBio Pharma stock?
BridgeBio Pharma (BBIO) has a market cap of $6.4B as of May 15, 2025.
What is the P/E ratio for BridgeBio Pharma stock?
The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of May 15, 2025.
Does BridgeBio Pharma stock pay dividends?
No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next BridgeBio Pharma dividend payment date?
BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for BridgeBio Pharma?
BridgeBio Pharma (BBIO) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.